Sachs David C. 4

What Happened
David C. Sachs, Chief Financial Officer of ImmunityBio, had 82,236 restricted stock units (RSUs vest) on February 10, 2026. The RSUs converted into common shares (reported as an exercise/conversion of a derivative at $0). To cover tax withholding, 42,643 shares were surrendered at a settlement price of $6.93 for a withholding value of $295,516. Net shares retained from the vesting event were 39,593, worth approximately $274,379 (based on the $6.93 price).

Key Details

• Transaction date: February 10, 2026; Form filed February 12, 2026 (timely filing).
• Vesting/settlement price: $6.93 (closing price used from February 9, 2026).
• Gross shares issued on vesting: 82,236 shares (value ≈ $569,895).
• Shares withheld for taxes: 42,643 shares (value $295,516).
• Net shares retained: 39,593 shares (value ≈ $274,379).
• Footnotes: Each RSU converts to one share; vesting occurred per the award schedule (vesting commencement Feb 10, 2025 with annual installments of ~33.33%/33.33%/33.34%).
• Shares owned after the transaction: not specified in the filing.
• Transaction codes: M = conversion/exercise of derivative (RSU settlement); F = shares withheld to satisfy tax liability.

Context
This was a scheduled RSU vesting event (award settlement) rather than an open-market purchase or discretionary sale. The disposition of shares here reflects tax withholding—common practice when equity awards vest—and does not necessarily indicate a broader buy/sell signal. The filing appears timely and consistent with routine equity compensation mechanics.